読み込み中
PMV Pharmaceuticals, Inc. operates as a precision oncology company focused on discovering and developing both small molecule and tumor-agnostic therapies to address p53 mutations in cancer patients. Their leading experimental drug, PC14586, is a small molecule designed to correct the p53 protein specifically when it contains the Y220C mutation, thereby restoring its natural, functional state. The company is also progressing a pipeline of other programs targeting various mutant p53 forms, including Wild-type p53 Induced-Phosphatase, R282W, R273H, and other prevalent p53 hotspot mutations. Originally known as PJ Pharmaceuticals, Inc., the firm rebranded to PMV Pharmaceuticals, Inc. in July 2013. The company was founded in 2013 and has its main operational base in Cranbury, New Jersey.
前日終値
$1.52
+$0.03 · +2.01%
日中の時刻はETです。市場データは遅延する場合があります。
PMV Pharmaceuticals, Inc. operates as a precision oncology company focused on discovering and developing both small molecule and tumor-agnostic therapies to address p53 mutations in cancer patients. Their leading experimental drug, PC14586, is a small molecule designed to correct the p53 protein specifically when it contains the Y220C mutation, thereby restoring its natural, functional state. The company is also progressing a pipeline of other programs targeting various mutant p53 forms, including Wild-type p53 Induced-Phosphatase, R282W, R273H, and other prevalent p53 hotspot mutations. Originally known as PJ Pharmaceuticals, Inc., the firm rebranded to PMV Pharmaceuticals, Inc. in July 2013. The company was founded in 2013 and has its main operational base in Cranbury, New Jersey.
日中レンジ
現在 $1.52
52週レンジ
現在 $1.52
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
売り
バリュエーション
30
割高
センチメント
62
強気
リスク
66
高リスク
モメンタム
35
弱含み
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
PMV Pharmaceuticals, Inc. operates as a precision oncology company focused on discovering and developing both small molecule and tumor-agnostic therapies to address p53 mutations in cancer patients. Their leading experimental drug, PC14586, is a small molecule designed to correct the p53 protein specifically when it contains the Y220C mutation, thereby restoring its natural, functional state. The company is also progressing a pipeline of other programs targeting various mutant p53 forms, including Wild-type p53 Induced-Phosphatase, R282W, R273H, and other prevalent p53 hotspot mutations. Originally known as PJ Pharmaceuticals, Inc., the firm rebranded to PMV Pharmaceuticals, Inc. in July 2013. The company was founded in 2013 and has its main operational base in Cranbury, New Jersey.
日中レンジ
現在 $1.52
52週レンジ
現在 $1.52
営業利益
純利益
| 指標（USD） | 2025年度 | 2024年度 | 2023年度 | 2022年度 | 2021年度 |
|---|---|---|---|---|---|
| 売上原価 | — | 114.4万 USD | 125.7万 USD | 65万 USD | 128.1万 USD |
| 粗利益 | — | −114.4万 USD | −125.7万 USD | −65万 USD | −128.1万 USD |
| 研究開発 | 6987.7万 USD | 5738.3万 USD | 5462.8万 USD | 5167.3万 USD | 3618.6万 USD |
| 販売・一般管理 | 1632.9万 USD | 2692.1万 USD | 2424.7万 USD | 2471.7万 USD | 2082.6万 USD |
| 営業費用 | 8620.6万 USD | 8430.4万 USD | 7887.5万 USD | 7639万 USD | 5701.2万 USD |
| 受取利息 | 633.7万 USD | 1065.5万 USD | 1117.1万 USD | 362.7万 USD | 44.9万 USD |
| 減価償却費と償却費 | 13.3万 USD | 114.4万 USD | 125.7万 USD | 31.5万 USD | 30.7万 USD |
| 営業利益 | −8620.6万 USD | −8544.8万 USD | −8013.2万 USD | −7704万 USD | −5829.3万 USD |
| 純利益 | −7774.2万 USD | −5870.9万 USD | −6896万 USD | −7331.7万 USD | −5784.6万 USD |
会社概要が更新されました 2026年10月11日.
直近の発表実績
第三者のアナリスト予想は変更される場合があり、GoAIの推奨ではありません。
平均目標
$5.00
上昇余地（228.95%）評価サンプルは4件と限定的です
この株式へのエクスポージャーを報告している上場投資信託です。
Vanguard Morningstar Total Stock Market ETFVTI179.93万0.00%2.3兆 USD0.03%$381.94+0.63%
Vanguard Extended Market ETFVXF54.74万0.00%954億 USD0.05%$235+0.80%
iShares Micro-Cap ETFIWC22.66万0.02%13.17億 USD0.60%$183+0.11%
EA Series Trust - EA Bridgeway Ultra-Small Company Market ETFBUSM11万0.10%1.17億 USD0.73%$15.9402+0.25%
Avantis Total Equity Markets ETF 1AVTM7026.84—7.94億 USD0.23%$55.6085+0.56%Vanguard Morningstar Total Stock Market ETFVTIVanguard Extended Market ETFVXFiShares Micro-Cap ETFIWCEA Series Trust - EA Bridgeway Ultra-Small Company Market ETFBUSMAvantis Total Equity Markets ETF 1AVTMAIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
